Cell Therapy Yields Promising Results For Scleroderma Treatment PDF Print E-mail
Tuesday, 24 September 2013 08:49
Cytori Therapeutics, Inc. provided preliminary data from a study evaluating a potential treatment for Scleroderma based on the company's cell therapy. The investigator-funded, open-label, pilot study is being conducted on patients with Cutaneous Systemic Scleroderma in France.

12 patients were administered Cytori's cell therapy, injected into their fingers. Safety and hand function improvement are the primary endpoints of the study which were measured by the Cochin hand functional scale at six months.

At the end of the two month follow-up period, no infection, ischemic complications or serious adverse events were observed. Moreover, there was a significant improvement in the Cochin hand function disability scale.

As far as secondary endpoints are concerned, there was a significant improvement in Scleroderma health assessment questionnaire score and in Raynaud's Severity Score. Also, there was a significant improvement in hand pain when measured by the visual analog pain scale.

Cytori is focused primarily on the development of treatments for cardiovascular disease and soft tissue injuries and burns based on its proprietary cell therapy formulation. The company's cell therapy is based on the formulation of stem and regenerative cells derived from a patient's own adipose (fat) tissue (ADRCs).

Source: NASDAQ (2013)
 
More articles :

» Role of ACE Inhibitors in Preventing Scleroderma Renal Crisis Remains Unclear

Scleroderma patients on angiotensin-converting enzyme inhibitors at the onset of Scleroderma renal crisis do not appear to have worse outcomes than do those not taking the antihypertensive agents prior to the acute renal function deterioration,...

» HSCT Benefits In Early Diffuse Cutaneous Systemic Sclerosis

Initial results from an international, investigator-initiated, open label phase 3 trial, presented at EULAR 2012, indicate that haematopoietic stem cell transplantation (HSCT) results in better long-term survival than conventional treatment for...

» Caribbean Autoimmune Disease Summit 2011

The Caribbean Autoimmune Disease Summit 2011, is scheduled to be held this Sunday 2nd October, 2011 at the , Port of Spain, Trinidad. Hosted by the Caribbean Investor Network, the Summit aims to raise awareness of Autoimmune Diseases, their...

» New Stem Cell Therapy To Help With Stubborn Wounds

The skin is the largest organ in the body with amazing healing powers, but what if your wounds didn't heal?That's the case for 6 million Americans suffering from chronic wounds that can take months, even years, to heal. Millions have no other choice...

» Finger Ulcers Still a Problem in Scleroderma

A significant number of patients with systemic sclerosis develop , greatly increasing their disease burden and the likelihood of complications, researchers reported here.For instance, 29.8% of patients with one or more digital ulcers developed...

» A New Marker of Silent Cardiovascular Disease in Diffuse Scleroderma

Patients with diffuse systemic sclerosis (SSc) and no clinical evidence of (CVD) may, in fact, have subclinical CVD and , and it is detectable. This is the conclusion of a small pilot study from Italy, which showed that elevated plasma levels of ...